Beth Schurman, Partner

Beth Schurman is a Partner at Herspiegel Consulting, a leading boutique consulting firm serving the Pharmaceutical and Biotechnology industries. Her strong leadership, attention to detail and client engagement skills have earned her the trust and respect of her clients. Beth leads teams of consultants and clients to expand their current thinking, structure and analyze business problems, and develop strategic and tactical solutions.

Beth successfully manages client project outcomes by expertly blending marketing strategy, innovative thinking, and rigorous structure to establish market changing strategies and impactful execution. Clients value her team’s ability to smoothly transition from strategy development & innovation to project management and analytics. Beth has led projects across our range of 5 core service areas and spanning therapeutic areas including diabetes, obesity, infectious disease, CNS and oncology.

Prior to her tenure with Herspiegel Consulting, Beth gained extensive marketing experience at both Novo Nordisk and BMS. She was highly involved in product launch, co-promotions and in-line brand management in retail and hospital markets.

Beth has a Bachelor of Arts in Biochemistry and Molecular Biology from Rutgers University. Beth then earned her MBA with specialization in Marketing and Management from the Stern School of Business at NYU.

Latest Blogs

Planning for 505(b)2 Commercial Success

October 17, 2018
Unlike generics and biosimilars, 505(b)2 regulatory products likely involve a unique claim. While 505(b)...
Read more

Fed-Up Hospitals are Starting Their Own Drug Company to Lower Generic Drug Prices

February 12, 2018
The impact of drug shortages is not new within the healthcare system, particularly at the hospital level...
Read more

FDA Continued Rejections of Citizen Petitions Highlights Key Lifecycle Challenges for Biologic Manufacturers

January 24, 2018
Citizen petitions have historically been a tool in the brand manufacturer’s toolkit of “product life...
Read more

The FDA approved Dupixent for moderate-to-severe atopic dermatitis

April 14, 2017
  The FDA approved Dupixent On March 28th, the FDA approved Dupixent for moderate-to-severe atopic ...
Read more